Drugs / pBCAR3-phosphopeptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01846143 | May 2013 → Jun 2015 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pBCAR3-phosphopeptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01846143 ↗ |
| Known as | pBCAR3126-134 | “HLA-A*0201-restricted phosphorylated BCAR3 peptide (pBCAR3126-134)” PMID 32385144 ↗ May 2020 |
| Modality | Vaccine | “a novel immunotherapic vaccine comprising either or both of these phosphorylated peptides” PMID 32385144 ↗ May 2020 |
| Route | Subcutaneous | “The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant” NCT01846143 ↗ |
| Target | BCAR3 | “a second phosphopeptide, from breast cancer antiestrogen resistance 3 (BCAR3)” PMID 32385144 ↗ May 2020 |